Navigation Links
Biodel Inc. Added to NASDAQ Biotechnology Index

DANBURY, Conn., May 13 /PRNewswire-FirstCall/ -- Biodel Inc. (Nasdaq: BIOD) today announced that the Company has been selected for inclusion in the NASDAQ Biotechnology Index (NBI), effective as of the market's open on Monday, May 19, 2008.

"We are pleased to be included in the NASDAQ Biotechnology Index and believe Biodel's inclusion is a result of the Company's consistent achievement of its goals," stated Dr. Solomon Steiner, Chairman and Chief Executive Officer of Biodel. "We look forward to reporting on future 2008 goals including the results from our two pivotal Phase III clinical trials for VIAject(TM) in September or October and the filing of our NDA submission for a suite of VIAject(TM) presentations by the end of 2008."

Launched in 1993, the NBI includes biotechnology and pharmaceutical companies listed on the NASDAQ National Market that meet minimum requirements for market value, average daily share volume and seasoning as a public company. The index is ranked on a semi-annual basis in May and November and serves as the basis for the iShares Nasdaq Biotechnology Index Fund (Amex: IBB). For more information about the Nasdaq Biotechnology Index, including eligibility criteria, visit

About Biodel Inc.

Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for endocrine disorders, such as diabetes and osteoporosis. Biodel's product candidates are developed by using VIAdel(TM) technology, which reformulates existing FDA- approved peptide drugs. The Company's lead product candidate, VIAject(TM), is an ultra rapid-acting injectable meal-time insulin in development for use by patients with Type 1 or Type 2 diabetes. VIAject(TM) is currently being tested in two pivotal Phase III clinical trials. Biodel's pipeline also includes VIAtab(TM), a sublingual tablet formulation of insulin in the Phase I stage of clinical testing, and two pre-clinical osteoporosis product candidates. For further information regarding Biodel, please visit the Company's website at


SOURCE Biodel Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Biodel Inc. Reports Second Quarter Fiscal Year 2008 Financial Results
2. Biodel Inc. to Present at the Bank of America 2008 Health Care Conference on May 13th 2008
3. Biodel Inc. to Present at the Morgan Stanley Global Healthcare Unplugged Conference April 30th 2008
4. Biodel Inc. to Present at the BioCentury Future Leaders Conference on March 27th, 2008
5. Biodel Inc. Reports First Quarter Fiscal Year 2008 Financial Results
6. Biodel Inc. to Announce First Quarter Fiscal Year 2008 Financial Results on February 14, 2008
7. Biodel Inc. Announces Pricing of Public Offering
8. Biodel to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on December 11, 2007
9. Brian J.G. Pereira, M.D. Joins Biodels Board of Directors
10. Biodel Inc. to Present at Natixis Bleichroeder Hidden Gems Conference on October 8, 2007
11. Biodel Inc. to Present at BIO InvestorForum 2007 Conference on October 11, 2007
Post Your Comments:
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample tracking software company, ... Crime Laboratory, has joined STACS DNA as a Field Application Specialist. , “I ... President and COO of STACS DNA. “In further expanding our capacity as a scientific ...
(Date:6/23/2016)... , June 23, 2016  Blueprint Bio, a company ... to the medical community, has closed its Series A ... Nunez . "We have received a commitment ... capital we need to meet our current goals," stated ... us the runway to complete validation on the current ...
(Date:6/23/2016)... CA (PRWEB) , ... June 23, 2016 , ... ... software, is exhibiting at the Pennsylvania Convention Center and will showcase its product’s ... conference. ClinCapture will also be presenting a scientific poster on Disrupting Clinical Trials ...
(Date:6/23/2016)... -- Amgen (NASDAQ: AMGN ) today announced a ... sciences incubator to accelerate the development of new therapies ... QB3@953 was created to help high-potential life science and ... stage organizations - access to laboratory infrastructure. ... "Amgen Golden Ticket" awards, providing each winner with one ...
Breaking Biology Technology:
(Date:6/1/2016)... Favorable Government Initiatives Coupled With ... Identification to Boost Global Biometrics System Market Through 2021  ... report, " Global Biometrics Market By Type, By ... 2011 - 2021", the global biometrics market is projected ... of growing security concerns across various end use sectors ...
(Date:5/9/2016)... 2016 Elevay is currently known ... freedom for high net worth professionals seeking travel for ... connected world, there is still no substitute for a ... sealing your deal with a firm handshake. This is ... advantage of citizenship via investment programs like those offered ...
(Date:4/26/2016)... , April 27, 2016 ... "Global Multi-modal Biometrics Market 2016-2020"  report to their ... , The analysts forecast the global ... of 15.49% during the period 2016-2020.  ... of sectors such as the healthcare, BFSI, transportation, ...
Breaking Biology News(10 mins):